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(HCV) infection in Australia and mortality from HCV infection
in a population cohort in Denmark: Two complementary
studies relevant to counseling patients
It is already well established that chronic HCV infection is associ-
ated with an increased risk for death and higher incidence of
hepatocellular carcinoma (HCC). However, less is known about
the burden of hospitalization in population cohorts of infected
patients as well as the impact of resolved viremia on over-all
mortality.
In this issue of the Journal of Hepatology, Gidding and co-
workers report hospital admission patterns expressed as stan-
dardized hospitalization ratios, in 82,601 mono-infected HCV
patients from New SouthWales, Australia (after exclusion of indi-
viduals with HBV and HIV co-infection as well as patients with
missing demographic information). Between 2000–2006, hospi-
talization rates across all age groups were 42% higher than
expected over-all as compared to the general population and
especially in 15–64 year old HCV patients. The greatest excess
was noted for 15–19 year old females. Lifestyle factors such as
illicit drug abuse, alcohol intake, and alcoholic liver disease were
among the major risk factors for hospitalization. As expected,
non-alcoholic liver disease and HCC were associated with a 14-
to 16-fold excess rate of hospital admissions. Finally, hospitaliza-
tion rates were also increased in HCV patients with renal failure
and diabetes mellitus.
In a second paper in this issue, Omland and co-workers con-
ducted a population based survey (from 1996 to 2005), compar-
ing mortality rates between patients who cleared HCV infection
to HCV patients with viremia (after exclusion of patients with
HIV). Out of 13,005 patients with chronic HCV infection, 6292
patients met the study criteria and were included in the analysis.
Clearance of HCV infection was established in 2323 patients
(37%), while 3969 were viremic (63%). Five year survival was
higher, while over-all mortality and liver related as well as
HCC-associated mortality were signiﬁcantly lower in HCV
patients who cleared viremia as compared to viremic patients.
The two studies have a number of common features. Both
were population surveys conducted in highly industrialized
countries with a well recorded patient population registry system
and excellent data bases using similar International Classiﬁcation
of Diseases ICD-8 and ICD-10 versions. Furthermore, the studyJournal of Hepatology 20
* Tel.: +972 26777337; fax: +972 26420338.
E-mail address: shouval@cc.huji.ac.ilpopulations in both reports from Australia and Denmark were
of similar size, ranging from 7 million to 5.4 million, respectively.
The statements that only 1.4% of infected HCV patients in Austra-
lia and 2% in Denmark had been treated for HCV should be of con-
cern to health policy makers. As stated in both reports, certain
risk-taking behavior, i.e., illicit drug abuse and alcohol intake,
contribute to the increased morbidity and mortality of patients
with chronic HCV infection. Many of the results obtained in both
studies conﬁrm previous observations regarding the natural his-
tory of HCV infection and the impact of anti-viral treatment on
survival. However, the two surveys are population based studies
which provide important information devoid of the selection bias
which is common for patient cohorts selected for clinical trials.
Despite a number of limitations including among others, the lack
of information on duration of HCV infection, viral load, and geno-
type, the fact that these studies were conducted in countries with
a relatively high income per capita, and without going into more
details, both studies contain important demographic and epide-
miologic information which will be useful for future counseling
of patients as well as for strategic planning for health authorities.New insight into the mechanism of hepatic involvement in
brucellosis
Brucellosis, historically called undulant, Mediterranean, or Malta
fever, is a zoonotic infection which has rarely attracted the atten-
tion of hepatologists in the last two decades. Infection may pres-
ent with fever of unknown origin, night sweats, malaise,
anorexia, arthralgias, fatigue, weight loss, and depression, and
is curable when properly treated and does not lead to cirrhosis.
It is caused in humans by one of four species: Brucella melitensis,
Brucella abortus, Brucella suis, and Brucella canis. Although rela-
tively rare in industrialized countries, these species are still fre-
quently found in various geographic regions worldwide, mainly
in domesticated animals as well as in humans who consume
unpasteurized dairy products or are occupationally exposed.
Having a predilection for the reticuloendothelial system (RES)
including bone marrow and lymphnodes, these organisms com-
monly affect the liver, being the largest RES organ [1,2]. Hepatic
involvement in Brucellosis comprises a clinical–pathological
spectrum, ranging from mild elevation of liver function tests,
hepatitis, granulomatous hepatitis, and liver abscess. The charac-
teristics of hepatic involvement were previously reported
through liver biopsies in a series of 40 Spanish patients with clin-
ical or biochemical evidence of liver disease in whom 65% had10 vol. 53 j 1–2
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hepatomegaly and 77% had mild to moderate impaired liver func-
tion tests [1]. Histologic manifestations can be schematically
divided into three categories, according to the organism involved:
(i) hepatitis: i.e., microaggregates of mononuclear cells within the
portal triads and/or larger aggregates extending into the paren-
chyma resembling viral hepatitis, and occasionally granulomas
formed by mononuclear cells and histiocytes; these features are
usually seen with B. melitensis; (ii) granulomatous hepatitis: usu-
ally caused by B. abortus and (iii) liver abscesses: usually caused
by B. suis infection. The human host response to infection was
until recently linked to an RES response to infection involving
B, NK and T cell mediated interferon-c response, activating mac-
rophages and inducing apoptosis. Patients with polymorphism in
the IFN-c gene have been shown to have a higher susceptibility to
infection as compared to controls [3]. The bacterium inhibits
TNF-a and impairs cytotoxicity of NK cells.
In this issue of the Journal of Hepatology, Delpino and co-
workers report the development of a new model for infection
and propagation of B. abortus in human hepatoma cells. In a series
of elegant and comprehensive experiments, these investigators
have shown for the ﬁrst time that hepatocytes and not only Kupf-
fer cells play a role in the innate immune response against Bru-
cella, leading to recruitment of inﬂammatory cells to the site of
infection. Infected hepatocytes secreted IL-8, induced migration2 Journal of Hepatology 2of neutrophils, and enhanced expression of ICAM-1 leading to
adhesion of neutrophils to the transformed hepatocytes. The pro-
inﬂammatory response of infected hepatoma cells was also asso-
ciated with target cell apoptosis. The results of these experiments
and the in-depth discussion provide new evidence regarding the
role of human hepatocytes (represented by human hepatoma
cells HepG2) in the defense against B. abortus and possibly also
against other strains of this bacterium.Conﬂicts of interest
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